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Purpose
We compared the efficacy of the herbal preparation of
myrrh, chamomile extract and coffee charcoal (herb)
with a mesalazine (mes) therapy in maintaining remis-
sion in ulcerative colitis (UC).
Methods
A total of 96 patients (51 female) with UC in remission
(not longer than 12 months) were included in a rando-
mized, double-blind, double-dummy, multicenter, non
inferiority study comparing mesalazine 500 mg (3x1/d) to
100mg myrrh, 70mg chamomile extract and 50mg coffee
charcoal (3 x 4/d) over a time period of 12 months. As pri-
mary outcome criterion, non-inferiority of the herbal pre-
paration was defined and accepted, if the difference in the
colitis activity index (Colitis Activity Index - CAI - Rachmi-
lewitz) (calculated at six time points during the 12 month
interval) averaged over all visits was ≤ 1p o i n t .F u r t h e r -
more, relapse rates, relapse-free times, safety, a comprehen-
sive activity index (CAI, CRP and fecal Lactoferrin,
Calprotectin and PMN-Elastasis), an endoscopic activity
index and Health-related Quality of life (HrQoL) were
assessed. Peripheral CD4+CD25+ reg T-cells were investi-
gated in a subgroup at each time point and during a flare.
Results
Primary outcome criterion (p = 0.19), relapse rates
(CAI>4) (mes 22/49 patients vs herb 25/47 patients; p =
0.54), relapse-free time (268 ± 22 days for mes and 240 ±
23 days (p = 0.40) for the herb), the comprehensive activ-
i t yi n d e xa n dH r Q o Ld i dn o ts h o was i g n i f i c a n td i f f e r -
ence. Of notice, peripheral CD4+CD25+ regulatory T-
cells showed a distinct different pattern at time points
pre-flare and flare for the two treatment modalities (CD4
+CD25+Treg mes p=non significant (ns); herb p=0.02;
CD4+CD25+ Treg high mes p=ns; herb p=0.008).
Conclusion
The herbal preparation shows efficacy and safety in
maintaining remission non-inferior to mesalazine in
ulcerative colitis. It appears to offer an alternative option
for maintenance therapy. Regulatory T-cell pattern
might give first evidence to suggest a different mechan-
ism of action.
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